News >

Emerging Modalities Abound in Stage III NSCLC Treatment

Ellie Leick
Published: Thursday, Oct 10, 2019

William T. Sause, MD

William T. Sause, MD

Treatment for patients with stage III non–small cell lung cancer (NSCLC) has significantly evolved over the past few decades to include better patient selection as well as chemoradiation, immunotherapy, and other modalities—all of which require further research, explained William T. Sause, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication